A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT01682759
First received: September 7, 2012
Last updated: January 6, 2016
Last verified: December 2015

September 7, 2012
January 6, 2016
September 2012
January 2015   (final data collection date for primary outcome measure)
  • Change From Baseline in Hemoglobin A1C at Week 54 [ Time Frame: Baseline and Week 54 ] [ Designated as safety issue: No ]
    Hemoglobin A1C is blood marker used to report average blood glucose levels over prolonged periods of time and is reported as a percentage (%). Thus, this change from baseline reflects the Week 54 A1C minus the Week 0 A1C.
  • Percentage of Participants Who Experienced at Least One Adverse Event Excluding Data After Glycemic Rescue [ Time Frame: Up to Week 57 ] [ Designated as safety issue: Yes ]
    An AE is defined as any unfavorable and unintended sign including an abnormal laboratory finding, symptom or disease associated with the use of a medical treatment or procedure, regardless of whether it is considered related to the medical treatment or procedure.
  • Percentage of Participants Who Discontinued From the Study Due to an Adverse Event Excluding Data After Glycemic Rescue [ Time Frame: Up to Week 54 ] [ Designated as safety issue: Yes ]
Change From Baseline in Hemoglobin A1C at Week 54 [ Time Frame: Baseline and Week 54 ] [ Designated as safety issue: No ]
Complete list of historical versions of study NCT01682759 on ClinicalTrials.gov Archive Site
  • Change From Baseline in Fasting Plasma Glucose at Week 54 [ Time Frame: Baseline and Week 54 ] [ Designated as safety issue: No ]
    Blood glucose was measured on a fasting basis. FPG is expressed as mg/dL. Blood was drawn at predose on Day 1 and after 54 weeks of treatment to determine change in plasma glucose levels (i.e., FPG at Week 54 minus FPG at baseline).
  • Percentage of Participants Achieving a Hemoglobin A1C of <6.5% at Week 54 [ Time Frame: Week 54 ] [ Designated as safety issue: No ]
    The percentage of participants who achieved A1C values <6.5% (48 mmol/mol) in the FAS Population at Week 54.
  • Percentage of Participants With an Adverse Event of Symptomatic Hypoglycemia Excluding Data After Glycemic Rescue [ Time Frame: Up to Week 54 ] [ Designated as safety issue: Yes ]
    Symptomatic episode of hypoglycemia was an episode with clinical symptoms reported by the investigator as hypoglycemia (concurrent fingerstick glucose not required).
  • Change From Baseline in Body Weight at Week 54 Excluding Data After Gylcemic Rescue [ Time Frame: Baseline and Week 54 ] [ Designated as safety issue: Yes ]
  • Percentage of Participants Achieving a Hemoglobin A1C of <7.0% at Week 54 [ Time Frame: Week 54 ] [ Designated as safety issue: No ]
    The percentage of participants who achieved A1C values <7.0% (53 mmol/mol) in the FAS Population at Week 54.
  • Change From Baseline in Fasting Plasma Glucose at Week 54 [ Time Frame: Baseline and Week 54 ] [ Designated as safety issue: No ]
  • Number of Participants Achieving a Hemoglobin A1C of <6.5% and <7.0% at Week 54 [ Time Frame: Week 54 ] [ Designated as safety issue: No ]
  • Number of Participants with an Adverse Event of Symptomatic Hypoglycemia [ Time Frame: Up to Week 54 ] [ Designated as safety issue: Yes ]
  • Change in Body Weight from Baseline at Week 54 [ Time Frame: Baseline and Week 54 ] [ Designated as safety issue: No ]
Not Provided
Not Provided
 
A Study of the Safety and Efficacy of Omarigliptin (MK-3102) Compared With Glimepiride in Participants With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin (MK-3102-016)
A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of MK-3102 Compared With the Addition of Glimepiride in Subjects With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin
This trial will assess the safety and efficacy of omarigliptin (MK-3102) compared with the sulfonylurea, glimepiride, in Type 2 diabetes mellitus participants with inadequate glycemic control on metformin monotherapy. The primay hypothesis of the study is that after 54 weeks, the mean change from baseline in hemoglobin A1C (A1C) in participants treated with omarigliptin is non-inferior compared with that in participants treated with glimepiride.
Not Provided
Interventional
Phase 3
Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Type 2 Diabetes Mellitus
  • Drug: Omarigliptin
  • Drug: Placebo to Omarigliptin
  • Drug: Glimepiride
    Glimepiride (1 mg and/or 2 mg tablets). During the 54-week double-blind treatment period, glimepiride can be up-titrated, as appropriate, to a maximum total daily dose of 6 mg/day. Throughout the trial, down-titration of glimepiride may also occur based upon the participant's glucose measurements and clinical symptoms of hypoglycemia.
    Other Names:
    • AMARYL®
    • GLIMY
  • Drug: Glimepiride Placebo
  • Drug: Metformin
    Participants will continue on their stable dose (>=1500 mg/day) of open-label metformin throughout the trial.
  • Drug: Insulin Glargine
    Insulin glargine can be used for rescue therapy, if glycemic control is not maintained. Insulin therapy should be initiated as per local country insulin glargine label.
  • Experimental: Omarigliptin
    Participants will receive omarigliptin, 25 mg once weekly and placebo matching glimepiride once daily for up to 54 weeks.
    Interventions:
    • Drug: Omarigliptin
    • Drug: Glimepiride Placebo
    • Drug: Metformin
    • Drug: Insulin Glargine
  • Active Comparator: Glimepiride
    Participants will receive glimepiride titrated to a maximum of 6 mg, once daily, and placebo to omarigliptin, once weekly for up to 54 weeks.
    Interventions:
    • Drug: Placebo to Omarigliptin
    • Drug: Glimepiride
    • Drug: Metformin
    • Drug: Insulin Glargine
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
751
January 2015
January 2015   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosed with Type 2 diabetes mellitus
  • On a stable dose of metformin (≥1500 mg/day) for at least 12 weeks with inadequate glycemic control
  • Females of reproductive potential agree to remain abstinent or use or have their partner use acceptable methods of birth control

Exclusion Criteria:

  • History of type 1 diabetes mellitus or a history of ketoacidosis
  • Treated with any antihyperglycemic agents (AHA) therapies other than the protocol-required metformin within the prior 12 weeks of study participation or with omarigliptin at any time prior to signing informed consent
  • On a weight loss program and is not in the maintenance phase or has

started a weight loss medication in the past 6 months or has undergone bariatric surgery within 12 months prior to study participation

  • Medical history of active liver disease (other than non-alcoholic

hepatic steatosis), including chronic active hepatitis B or C, primary biliary cirrhosis, or symptomatic gallbladder disease

  • Human immunodeficiency virus
  • New or worsening coronary heart disease, congestive heart failure, myocardial infarction, unstable angina, coronary artery intervention, stroke or transient ischemic neurological disorder within the past 3 months
  • History of malignancy ≤5 years prior to study participation except for adequately treated basal cell or squamous cell skin cancer, or in situ

cervical cancer

  • Clinically important hematological disorder (such as aplastic anemia,

myeloproliferative or myelodysplastic syndromes, thrombocytopenia)

  • Pregnant or breast-feeding, or is expecting to conceive or donate eggs

during the trial, including 21 days following the last dose of study drug

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
Croatia,   Germany,   Hungary,   Korea, Republic of,   Lebanon,   Lithuania,   Malaysia,   Poland,   Romania,   United States
 
NCT01682759
3102-016, MK-3102-016
Yes
Not Provided
Not Provided
Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
Not Provided
Study Director: Medical Director Merck Sharp & Dohme Corp.
Merck Sharp & Dohme Corp.
December 2015

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP